Catalent will add biologics drug substance production capabilities to its Italian plant, which it says will support demand from the European market. The $100 million investment will see contract development manufacturing organization (CDMO) Catalent install two 2,000 L single-use bioreactors in newly constructed manufacturing suites at its Anagni, Italy facility it acquired from Bristol Myers Squibb in June 2019. Additionally, the firm will build infrastructure required to house a further six 2,000 L single-use bioreactors and the first phase of…
